Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis

Acta Haematologica

Volumn 108, Issue 3, 2002, Pages 113-119

  Reilly, John T ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

13q; 20q; Cytogenetics; Idiopathic myelofibrosis; Prognosis; Trisomy 1q

Indexed keywords

ANDROGEN; CALMODULIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CELL PROLIFERATION; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CLONAL VARIATION; FIBROBLAST; GENETIC ANALYSIS; HEMATOPOIETIC CELL; HUMAN; KARYOTYPING; LEUKEMIA; MYELOFIBROSIS; ONCOGENE; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REVIEW; TRISOMY; TRISOMY 7; TRISOMY 8;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; MYELOFIBROSIS; TRISOMY;

EID: 0036423705     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064708     Document Type: Review

References (89)

1. Ward HP, Block MH: The Natural History of Agnogenic Myeloid Metaplasia (AMM) and a Critical Evaluation of its Relationship with the Myeloproliferative Syndrome Medicine (Baltimore) 1971;50:357-420.
2. Heuck G: Zwei Fälle von leukämie mit eigentümlichem blut- resp. Knockenmarksbefund. Virchows Archiv 1879;78:475-496.
3. Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375.
4. Mesa RA, Li CY, Schroeder G, Tefferi A: Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001;97:3665-3667.
5. Kutti J, Ridell B: Epidemiology of the myeloproliferative disorders: Essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001;49:164-166.
6. Chaiter Y, Brenner B, Aghai E, Tatarsky I: High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymph 1992;7:251-255.
7. Andersen RE, Hoshino T, Yamamoto T: Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. Ann Intern Med 1964;60:1-18.
8. Johnson SA, Bateman CJ, Beard ME, Whitehouse JM, Water AH: Long-term haematological complications of thorotrast. Q J Med 1977;182:259-271.
9. Rawson R, Parker F, Jackson H: Industrial solvents as possible etiologic agents in myeloid metaplasia. Science 1941;93:541-542.
10. Hu H: Benzene-associated myelofibrosis. Ann Intern Med 1987;106:171-173.
11. Bosch X, Campistol JM, Montoliu J, Cervantes F, Revert, L: Toluene-associated myelofibrosis. Blut 1989;58:219-220.
12. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663.
13. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978;51:189-194.
14. Lucas GS, Padua RA, Masters GS, Oscier D, Jacobs A: The application of X chromosome gene probes to the diagnosis of myeloproliferative disease. Br J Haematol 1989;72:530-533.
15. Kreipe H, Jaquet K, Felgner J, Radzun H-J, Parwaresch MR: Clonal granulocytes and marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991;78:1814-1817.
16. Anger B, Janssen JW, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR: Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 1990;4:258-261.
17. Taylor KM, Shetta M, Talpaz M, Kantarjian HM, Hardikar S, Chinault AC, McCredie KB, Spitzer G: Myeloproliferative disorders: Usefulness of X-linked probes in diagnosis. Leukemia 1989;3:419-422.
18. Gale RE, Wheadon H, Boulos P, Linch DC: Tissue specificity of X-chromosome inactivation patterns. Blood 1994;83:2899-2905.
19. Tsukamoto N, Morita K, Maehara T, Okamoto K, Sakai H, Karasawa M, Naruse T, Omine M: Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: Demonstration of heterogeneity in lineage involvement. Br J Haematol 1994;86:253-258.
20. Asimakopoulos FA, Gilbert JG, Aldred MA, Pearson TC, Green AR: Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood 1996;88:2690-2698.
21. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM: Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984;57:495-503.
22. Han ZC, Briere J, Nedellec G, Abgrall JF, Senzebe L, Parent D, Guern G: Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with myelofibrosis. Eur J Haematol 1988;40:130-135.
23. Carlo-Stella C, Cazzola M, Gasner A, Barosi G, Dezza L, Meloni F, Pedrazzoli P, Hoelzer D, Ascari E: Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E and CFU-GM) from patients with myelofibrosis and myeloid metaplasia. Blood 1987;70:1014-1019.
24. Colovic MD, Wiernik PH, Jankovic GM, Vidovic AD, Janosevic S, Basara NM: Circulating haematopoietic progenitor cells in primary and secondary myelofibrosis: Relation to collagen and reticulin fibrosis. Eur J Haematol 1999;62:155-159.
25. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, Frassoni F: Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-3255
26. Castro-Malaspina H, Gay RE, Thanwar SL: Characteristics of bone marrow fibroblast colony forming cells and their progeny in patients with myeloproliferative disorders. Blood 1982; 59:1046-1056.
27. Guardiola P, Esperou H, Cazals-Hatem D, Ifrah N, Jouet J-P, Buzyn A, Sutton L, Gratecos N, Tilly H, Lioure B, Gluckman E: Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997;98: 1004-1009.
28. Rameshwar P, Denny TN, Stein D, Gascon P: Monocytic adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol 1994;15: 2819-2830.
29. Reilly JT: Idiopathic myelofibrosis: Pathogenesis, natural history and management. Blood Rev 1997;11:233-242.
30. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P: Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 1992;80:184-188.
31. Zhang B, Lewis SM: The splenomegaly of myeloproliferative and lymphoproliferative disorders: Splenic cellularity and vascularity. Eur J Haematol 1989;43:63-66.
32. Mesa RA, Li CY, Schroeder G, Tefferi A: Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 2001;97:3665-3667.
33. Demory JL, Dupriez B, Fenaux P, Lai JL, Beuscart R, Jouet JP, Derminatti M, Bauters F: Cytogenetic studies and their prognostic significance in agnogeneic myeloid metaplasia: A report on 47 cases. Blood 1988;72:855-859.
34. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watemore A, Potter A: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol 1997;98:96-102.
35. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li C-Y, Dewald GW: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;113: 763-771.
36. Bench AJ, Nacheva EP, Champion KM, Green AR: Molecular genetics and cytogenetics of myeloproliferative disorders. Baillières Clin Haematol 1998;11:819-848.
37. Reilly JT, Wilson J, Barnett D, Watmore A, Potter, A: Karyotypic and ras gene mutation analysis in idiopathic myelofibrosis. Br J Haematol 1994;88:575-581.
38. Dupriez B, Morel P, Demory J-L, Lai JL, Simon M, Plantier I, Bauters F: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
39. Trautmann U, Rubbert A, Gramatzki M, Henschke F, Gebhart E: Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis. Cancer Genet Cytogenet 1992;61:6-10.
40. Kerim S, Rege-Cambrin G, Scaravaglio P, Godio L, Saglio G, Aglietta M: Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. Cancer Genet Cytogenet 1991;52:63-69.
41. Morris CM, Cochrane JM, Benjes SM, Crossen PE, Fitzgerald PH: Molecular definition of interstitial deletions of chromsome 13 in leukaemia cells. Genes Chromosomes Cancer 1991;3:455-460.
42. Lebowitz P, Papac R, Ghosh PK: Impaired retinoblastoma suscepibility (Rb) gene expression in agnogenic myeloid metaplasia. Blood 1990;76(suppl 1): 236a.
43. Pastore C, Nomdedeu J, Volpe G, Guerrasio A, Cambrin GR, Parvis G, Pautasso M, Daglio C, Mazza U, Saglio G, Gaidano G: Genetic analysis of chromosome 13 deletions in bcr/abl negative chronic myeloproliferative disorders. Genes Chromosomes Cancer 1995;14:106-111.
44. Juneau AL, Kaehler M, Christensen ER, Schad CR, Zinsmeister AR, Lust J, Hanson C, Dewald GW: Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genet Cytogenet 1998;103:117-123.
45. Tanaka K, Arif M, Eguchi M, Guo SX, Hayashi Y, Asaoku H, Kyo T, Dohy H, Kamada N: Frequent allelic loss of the RB, D13S319 and D13S25 locus in myeloid malignancies with deletion/translocation at 13q14 of chromosome 13, but not in lymphoid malignancies. Leukemia 1999;13:1367-1373.
46. Sinclair EJ, Forrest EC, Reilly JT, Watemore AE, Potter AM: Fluorescence in situ hybridization analysis of 25 cases of idiopathic myelofibrosis and two cases of secondary myelofibrosis: Monoallelic loss of RB1, D13S319 and D13S25 loci associated with cytogenetic deletion and translocation involving 13q14. Br J Haematology2001;113:365-368.
47. La Starza R, Wlodarska I, Aventin A, Falzetti B, Crescenzi B, Martelli MF, van de Berghe H, Mecucci C: Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 1998;91:231-237.
48. Dewald GW, Wright PI: Chromosome abnormalities in the myeloproliferative disorders. Semin Oncol 1995;22:341-354.
49. Gardiner AC, Corcoran MM, Oscier DG: Cytogenetic, fluorescence in situ hybridisation and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphatic leukemia. Genes Chromosomes Cancer 1997;20:73-81.
50. Hawthorn LA, Chapman R, Oscier D, Cowell JK: The consistent 13q14 translocation breakpoint in chronic B-cell leukemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 1993;8:1415-1419.
51. Macdonald DHC, Lahiri D, Chase A, Sohal J, Goldman JM, Cross NCP: A case of myelofibrosis with a t(4;13)(q25;q12): Evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders. Br J Haematol 1999;105:771-774.
52. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F: Karyotypic patterns in chronic myeloproliferative disorders: Report on 74 cases and review of the literature. Leukemia 1991;5:214-220.
53. Nacheva E, Holloway T, Carter N, Grace C, White N, Green AR: Characterization of 20q deletions in patients with myeloproliferative disorders and myelodysplastic syndromes. Cancer Genet Cytogenet 1995;80:87-94.
54. Roulston D, Espinosa R, Stoffel M, Bell GI, Le Beau MM: Molecular genetics of myeloid leukemia: Identification of the commonly deleted segment of chromosome 20. Blood 1993;82: 3424-3429.
55. Wang PW, Eisenbart JD, Espinosa R, Davis EM, Larson RA, Le Beau MM: Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 2000;67:28-39.
56. MacGrogan D, Alvarez S, DeBlasio T, Jhanwar SC, Nimer SD: Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines. Oncogene 2001; 20:4150-4160.
57. Rowley JD: Abnormalities of chromosome no 1 in haematological malignancies. Lancet 1978;i:554-555.
58. Gahrton G, Friburg K, Lindsten J, Zech L: Duplication of part of the long arm of chromosome 1 in myelofibrosis terminating in acute myeloblastic leukemia. Hereditas 1978;88:1-5.
59. Donti E, Tabilio A, Bocchini F, Falzetti F, Martelli MF, Grignani F, Donti GV: Partial trisomy 1q in idiopathic myelofibrosis. Leuk Res 1990;14:1035-1040.
60. Zanke B, Squire J, Griesser H, Henry M, Suzuki H, Patterson B, Minden M, Mak TW: A hematopoietic protein tyrosine phosphatase (hePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia 1994;8:236-244.
61. Geraedts JPM, den Ottolander GJ, Ploem JE, Muntinghe OG: An identical translocation between chromosome 1 and 7 in three patients with myelofibrosis and myeloid metaplasia. Br J Haematol 1980;44:569-575.
62. Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux JL, Offner F, Saglio G, Van den Berghe H: Extra translocation +der(1q9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 1991;5:1059-1063.
63. Whang-Peng J, Lee E, Knutsen T, et al: Cytogenetic studies in patients with myelofibrosis and myeloid metaplasia. Leuk Res 1978;2:41-56.
64. Miller JB, Testa JR, Lindgren V, Rowley JD: The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 1985;55:582-591.
65. Varki A, Lottenberg R, Griffith R, Reinhard E: The syndrome of idiopathic myelofibrosis: A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine 1983;62:353-371.
66. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E: A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988;70:397-401.
67. Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, Stamberg J, Davey FR, Schiffer CA, Bloomfield CD: Patients with trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: Results from Cancer and Leukemia Group B 8461. Clin Cancer Res 1998;4:1235-1241.
68. Sole E, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, Prieto F, Granada I, Hernandez JM, Cigudosa JC, Diez JL, Bureo E, Marques ML, Arranz, E, Rios R, Martinez Climent JA, Vallespi T, Florensa L, Woessner S: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000; 108:346-356.
69. Besa EC, Nowell PC, Geller NL, Gardner FH: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies predicting response and survival. Cancer 1982;49:308-313.
70. Hsu LY, Greenberg ML, Kohan S, Wittman R: Trisomy 13 in bone marrow cells in acute myelocytic leukemia and myelofibrosis. Clin Genet 1979;15:327-331.
71. Zojer N, Meran JG, Vesely M, Gruner H, Ackermann J, Dellinger C, Zimmer-Roth I, Heinz R, Drach J, Ludwig H: Trisomy 13 is associated with poor prognosis in idiopathic myelofibrosis with myeloid metaplasia. Leuk Lymph 1999;35:415-421.
72. Ferrara F, Vicari L, Festa B, Di Noto R, Pane F, Sebastio L, Cimino R: Trisomy 13 in a case of myelofibrosis with myeloid metaplasia with early blastic transformation. Haematologica 1995;80:434-436.
73. Cox MC, Panetta P, Venditti A, Abruzzese E, Del Poeta G, Cantone M, Amadori S: New reciprocal translocation t(6;10)(q27;q11) associated with idiopathic myelofibrosis. Leuk Res 2001;25:349-351.
74. Patton WN, Bunce CM, Larkins S, Brown G: Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality. Br J Cancer 1991;64:128-131.
75. Cervantes F, Barosi G, Demory J-L, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E: Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998;102:684-690.
76. Cervantes F, Barosi G, Hernández-Boluda J-C, Marchetti M, Montserrat E: Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: Presenting features, evolution and survival. Eur J Haematol 2001;66: 324-327.
77. Altura RA, Head DR, Wang WC: Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol 2000;109:459-462.
78. Tefferi A, Meyer RG, Wyatt WA, Dewald GW: Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;115:316-319.
79. Janssen JWG, Steenvoorden ACM, Lyons J, Anger B, Bohlke JU, Bos JL, Seliger H, Bartram CR: Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 1987;84: 9228-9232.
80. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR: Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterised by a N-ras gene mutation. Leukemia 1988;2:658-660.
81. Gaidano G, Guerrasio A, Serra A, Carozzi F, Cambrin GR, Petroni D: Mutations in the p53 and ras family genes are associated with tumour progression of bcr/abl negative chronic myeloproliferative disorders. Leukemia 1993; 7:946-953.
82. Siitonen T, Savolainen ER, Koistinen P: Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 1994;8:631-637.
83. Siitonen T, Zheng A, Savolainen E-R, Koistinen P: Spontaneous granulocyte-macrophage colony growth by peripheral blood mononuclear cells in myeloproliferative disorders. Leuk Res 1996;20:187-195.
84. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, Kuramoto A, Satow Y: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:661-663.
85. Kimura A, Nakata Y, Katoh O, Hyodo H: c-kit mutations in patients with myeloproliferative disorders. Leuk Lymph 1997;25:281-287.
86. Moliterno AR, Siebel KE, Sun AY, Hankins WD, Spivak JL: A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells 1998;16(suppl 2): 185-192.
87. Taskin AL, Cohen-Sokal K, Le Couedic JP, Abina MA, Villeval JL, Debili N, Casadevall N, Vainchenker W, Wendling F: Myelofibrosis: Experimental models and human studies. Stem Cells 1998;16(suppl 2):155-164.
88. Wang JC, Chen W, Nallusamy S, Chen C, Nov-etsky AD: Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukemic transformation. Br J Haematol 2002;116:582-586.
89. Jones LC, Tefferi A, Wachsman W, Hofmann WK, Koeffler HP: Detection of aberrant signalling pathways in CD34+ cells from patients with myelofibrosis with myeloid metaplasia using oligonucleotide microarrays. Blood 2001; 98(suppl):626a.